KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted) (2020 - 2025)

Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $1.53 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 15200.0% year-over-year to $1.53; the TTM value through Dec 2025 reached $2.08, up 4060.0%, while the annual FY2025 figure was $2.07, 5075.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.53 in Q4 2025 per AUPH's latest filing, up from $0.23 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.53 in Q4 2025 to a low of -$0.4 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.03, with a median of -$0.08 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 73.91% in 2021, then skyrocketed 15200.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.25 in 2021, then rose by 28.0% to -$0.18 in 2022, then fell by 5.56% to -$0.19 in 2023, then soared by 105.26% to $0.01 in 2024, then surged by 15200.0% to $1.53 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EPS (Weighted Average and Diluted) are $1.53 (Q4 2025), $0.23 (Q3 2025), and $0.16 (Q2 2025).